Edmond DE Rothschild Holding S.A. decreased its position in shares of Moderna, Inc. (NASDAQ:MRNA – Get Rating) by 2.3% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 140,543 shares of the company’s stock after selling 3,336 shares during the period. Edmond DE Rothschild Holding S.A.’s holdings in Moderna were worth $20,077,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in MRNA. Total Clarity Wealth Management Inc. purchased a new stake in Moderna during the second quarter valued at about $25,000. Oliver Lagore Vanvalin Investment Group bought a new position in shares of Moderna during the first quarter valued at about $30,000. FinTrust Capital Advisors LLC grew its stake in shares of Moderna by 754.5% during the second quarter. FinTrust Capital Advisors LLC now owns 188 shares of the company’s stock valued at $31,000 after buying an additional 166 shares during the last quarter. Legacy CG LLC bought a new position in shares of Moderna during the second quarter valued at about $34,000. Finally, OLD Second National Bank of Aurora bought a new position in shares of Moderna during the first quarter valued at about $39,000. Hedge funds and other institutional investors own 60.76% of the company’s stock.
Insiders Place Their Bets
In other Moderna news, insider Shannon Thyme Klinger sold 478 shares of the firm’s stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $137.44, for a total value of $65,696.32. Following the completion of the sale, the insider now directly owns 3,949 shares in the company, valued at $542,750.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Shannon Thyme Klinger sold 478 shares of Moderna stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $137.44, for a total transaction of $65,696.32. Following the completion of the transaction, the insider now directly owns 3,949 shares in the company, valued at $542,750.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Stephane Bancel sold 40,000 shares of Moderna stock in a transaction that occurred on Thursday, October 20th. The shares were sold at an average price of $120.83, for a total transaction of $4,833,200.00. Following the transaction, the chief executive officer now owns 5,411,946 shares of the company’s stock, valued at $653,925,435.18. The disclosure for this sale can be found here. Insiders sold 483,436 shares of company stock worth $64,832,812 over the last three months. Company insiders own 17.30% of the company’s stock.
Wall Street Analysts Forecast Growth
Moderna Stock Down 1.5 %
MRNA traded down $2.78 on Thursday, hitting $176.81. The company had a trading volume of 2,311,841 shares, compared to its average volume of 4,704,397. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.10 and a quick ratio of 1.80. Moderna, Inc. has a 52-week low of $115.03 and a 52-week high of $376.65. The stock has a fifty day simple moving average of $143.11 and a 200-day simple moving average of $146.64. The firm has a market capitalization of $67.93 billion, a P/E ratio of 6.40, a P/E/G ratio of 1.28 and a beta of 1.74.
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.
- Get a free copy of the StockNews.com research report on Moderna (MRNA)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.